Class summary at a glance.

Every drug in the SLAMF7-directed Immunostimulatory Antibody class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $3.5Mcombined across class
Total Rx claims: 34855 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Elotuzumab

Brand: EMPLICITI · 348 Part D claims (CY24) · 55 beneficiaries · First FDA approval: 2015-11-30

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $3.5M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.